CAR-T CD19 for Acute Lymphocytic Leukemia

Home / Clinical Studies / CAR-T CD19 for Acute Lymphocytic Leukemia

CAR-T CD19 for Acute Lymphocytic Leukemia

Chimeric Antigen Receptor T cell (CAR-T) therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors.

TRIAL DATA Phase I Clinical Trial – VIEW PRESS HERE March 25, 2015

Name of StudyClinical Study of Chimeric CD(Cluster of Differentiation)19 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas
PhaseClinical Trial Phase I
ClinicalTrials.gov IdentifierNCT01864889 - view study online here
Study TypeInterventional
Study DesignEndpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Principal InvestigatorWei Dong Han, MD, PhD
Hospital(s)Chinese PLA General Hospital (PLAGH)